Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard H Feldman

Showing results (41-50 of 160) with videos related to

Pageof 16
Sort By:
Neurobiology of Aging|November 2, 2013
Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian populationArdeshir Omoumi, Alice Fok, Talitha Greenwood, et al.
Alzheimer'S Research & Therapy|March 12, 2025
Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's diseaseGabriel L Ketron, Felix Grun, Joshua D Grill, et al.
International Journal of Geriatric Psychiatry|September 22, 2009
Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's diseaseKrista L Lanctôt, Ging-Yuek R Hsiung, Howard H Feldman, et al.
Stroke|July 19, 2008
Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer diseaseHoward H Feldman, Luis F Maia, Ian R A Mackenzie, et al.
International Journal of Geriatric Psychiatry|November 6, 2008
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular diseaseHoward H Feldman, Tuula Pirttila, Jean François Dartigues, et al.
Alzheimer Disease and Associated Disorders|June 30, 2009
Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezilRoy W Jones, Elias Schwam, David Wilkinson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 12, 2025
Implications of practice effects for the design of Alzheimer clinical trialsJasmin A Duehring, Diane M Jacobs, Michael L Thomas, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 1, 2020
Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measuresSarah J Banks, Yuqi Qiu, Chun Chieh Fan, et al.
Journal of the American Medical Directors Association|July 5, 2022
A Matter for Life and Death: Managing Psychological Trauma in Care HomesCarole A Estabrooks, Heather K Titley, Trina Thorne, et al.
Journal of Alzheimer'S Disease : JAD|April 29, 2017
The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade LaterAmir A Sepehry, Philip E Lee, Ging-Yuek R Hsiung, et al.
Pageof 16

Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Neurobiology of Aging|November 2, 2013
Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian populationArdeshir Omoumi, Alice Fok, Talitha Greenwood, et al.
Alzheimer'S Research & Therapy|March 12, 2025
Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's diseaseGabriel L Ketron, Felix Grun, Joshua D Grill, et al.
International Journal of Geriatric Psychiatry|September 22, 2009
Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's diseaseKrista L Lanctôt, Ging-Yuek R Hsiung, Howard H Feldman, et al.
Stroke|July 19, 2008
Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer diseaseHoward H Feldman, Luis F Maia, Ian R A Mackenzie, et al.
International Journal of Geriatric Psychiatry|November 6, 2008
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular diseaseHoward H Feldman, Tuula Pirttila, Jean François Dartigues, et al.
Alzheimer Disease and Associated Disorders|June 30, 2009
Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezilRoy W Jones, Elias Schwam, David Wilkinson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 12, 2025
Implications of practice effects for the design of Alzheimer clinical trialsJasmin A Duehring, Diane M Jacobs, Michael L Thomas, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 1, 2020
Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measuresSarah J Banks, Yuqi Qiu, Chun Chieh Fan, et al.
Journal of the American Medical Directors Association|July 5, 2022
A Matter for Life and Death: Managing Psychological Trauma in Care HomesCarole A Estabrooks, Heather K Titley, Trina Thorne, et al.
Journal of Alzheimer'S Disease : JAD|April 29, 2017
The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade LaterAmir A Sepehry, Philip E Lee, Ging-Yuek R Hsiung, et al.
Pageof 16